Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Key facts

Sponsor

TJ Biopharma Co., Ltd.

Principal Investigator

Liyang Song, Master

I-Mab Biopharma US Limited

Intervention

TJ107 +Pembrolizumab(biological)

Enrollment

133 enrolled

Eligibility

18 years · All sexes

Timeline

2021 – 2024

Study locations (20)

• The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
• The Second Hospital of Anhui Medical University, Hefei, Anhui, China
• Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality, China
• Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangzhou, China
• Hainan General Hospital, Haikou, Hainan, China
• Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
• Hubei Cancer Hospital, Wuhan, Hubei, China
• Tongji Hospital, Tongji Medical College of Huzhong University of Science and Technology, Wuhan, Hubei, China
• The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
• Jilin Cancer Hospital, Changchun, Jilin, China
• Jilin Guowen Hospital, Changchun, Jilin, China
• The First Hospital of Jilin University, Changchun, Jilin, China
• Yanbian University Hospital, Yanji, Jilin, China
• The First Hospital of China Medical University, Shenyang, Liaoning, China
• Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of head and neck

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07333274
  Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
  Shandong Cancer Hospital and Institute
• RECRUITINGPHASE3NCT07026474
  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
  Universität des Saarlandes
• RECRUITINGPHASE1NCT07182149
  A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
  Normunity AccelCo, Inc.
• RECRUITINGNANCT07203911
  Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
  Tobias Todsen
• RECRUITINGNANCT07180901
  Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer
  Centre hospitalier de l'Université de Montréal (CHUM)
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415
  Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
  China Medical University Hospital
• RECRUITINGPHASE2NCT07088211
  Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
• RECRUITINGPHASE2NCT07040956
  A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
  West China Hospital

See all trials for Squamous cell carcinoma of head and neck →